skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Metatinib Tromethamine (Code C113294)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Metatinib Tromethamine

Definition: An orally bioavailable tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL tyrosine kinase inhibitor BL001 may inhibit the BCL-ABL protein, which may lead to decreased proliferation and enhanced apoptosis in tumor cells. BCR-ABL oncoprotein is generated by a reciprocal translocation between chromosome 9 and 22 specifically t(9;22)(q34;q11). The resulting fusion gene produces proteins with constitutively active tyrosine kinase activity, which stimulate both abnormal cell division and increased cellular proliferation. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia.

Label: Metatinib Tromethamine

NCI Thesaurus Code: C113294 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL458141  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
BCR-ABL Tyrosine Kinase Inhibitor BL001
Metatinib Tromethamine

External Source Codes: 
PDQ Closed Trial Search ID 755994
PDQ Open Trial Search ID 755994 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C113294
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom